Biblio

Export 66 results:
[ Author(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, et al.. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A [Internet]. 1998;95(2):548 - 53. http://view.ncbi.nlm.nih.gov/pubmed/9435229PDF icon Marc Achen et al., PNAS 1998 (447.59 KB)
Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, et al.. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE [Internet]. 2010;5(11):e14109. http://view.ncbi.nlm.nih.gov/pubmed/21124841PDF icon Imke Albrecht et al., PLoS One 2010 (3.37 MB)
Anisimov A, Tvorogov D, Alitalo A, Leppänen V-M, An Y, Han EC, et al.. Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis. Circulation. 2013;127(4):424-434. PDF icon Anisimov 2013 (6.56 MB)PDF icon Anisimov 2013 Supplement (4.93 MB)
Anisimov A, Alitalo A, Korpisalo P, Soronen J, Kaijalainen S, Leppänen V-M, et al.. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res [Internet]. 2009;104(11):1302 - 12. http://view.ncbi.nlm.nih.gov/pubmed/19443835PDF icon Andrey Anisimov et al., Circulation Research 2009 (8.03 MB)PDF icon Andrey Anisimov et al., Circulation Research 2009, supplement (5.9 MB)
Anisimov A, Leppänen V-M, Tvorogov D, Zarkada G, Jeltsch M, Holopainen T, et al.. The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. Sci Signal. 2013;6(282):ra52. PDF icon Anisimov 2013 Science Signaling (1.92 MB)PDF icon Anisimov 2013 Science Signaling Supplement (2.09 MB)
B
Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, et al.. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest [Internet]. 2005;115(2):247 - 57. http://view.ncbi.nlm.nih.gov/pubmed/15668734PDF icon Peter Baluk et al., Journal of Clinical Investigation 2005 (1.89 MB)
Batchu KChaithanya, Hokynar K, Jeltsch M, Mattonet K, Somerharju P. Substrate efflux propensity is the key determinant of iPLA-β-mediated glycerophospholipid hydrolysised. Journal of Biological Chemistry [Internet]. 2015;. http://www.jbc.org/content/early/2015/02/23/jbc.M115.642835.abstractPDF icon J. Biol. Chem.-2015-Batchu-jbc.M115.642835.pdf (786.13 KB)
Batchu KChaithanya, Hänninen S, Jha SKumar, Jeltsch M, Somerharju P. Factors regulating the substrate specificity of cytosolic phospholipase A2-alpha in vitro. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2016;1861(11):1597. PDF icon Batchu et al. - 2016 - Factors regulating the substrate specificity of cy.pdf (986.25 KB)
Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, et al.. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974PDF icon Maija Bry et al., Circulation 2010 (2.23 MB)PDF icon Maija Bry et al., Circulation 2010, supplement (17.77 MB)
H
He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, et al.. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292PDF icon Yulong He et al., Cancer Research 2005 (1.82 MB)
Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, et al.. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522PDF icon Caroline Heckman et al., Cancer Research 2008 (504.8 KB)
Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Wedge SR, et al.. Inhibiton of VEGF-C-induced VEGFR-3 activity and lymphatic endothelial cell function by the tyrosine kinase inhibitor AZD2171. In 98th Annual Meeting of the American-Association-for-Cancer-Research [Internet]. Los Angeles, CA: American Association for Cancer Research; 2007. http://dx.doi.org/10.1158/0008-5472.CAN-07-5809PDF icon Heckman et al. - 2007 - Inhibiton of VEGF-C-induced VEGFR-3 activity and l.pdf (236.37 KB)
Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, et al.. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation [Internet]. 2000;102(18):2262 - 8. http://view.ncbi.nlm.nih.gov/pubmed/11056103PDF icon Mikko Hiltunen et al., Circulation 2000 (1.44 MB)
J
Jeltsch M. What you should know about VEGF-C when working with lymphatics [German]. In Lymphologie 2017 [Internet]. Bad Soden (Frankfurt), Germany; 2017. https://jeltsch.org/Abstrakt-BadSoden2017PDF icon Extended Abstract (published in Vasomed, 2018) (226.5 KB)
Jeltsch M, Tammela T, Alitalo K, Wilting J. Genesis and pathogenesis of lymphatic vessels. Cell Tissue Res [Internet]. 2003;314(1):69 - 84. http://view.ncbi.nlm.nih.gov/pubmed/12942362PDF icon Michael Jeltsch et al., Cell and Tissue Research 2003 (562.33 KB)
Jeltsch M, Alitalo K. VEGF Receptors. In Sigma-RBI Handbook of Receptor Classification and Signal Transduction [Internet]. 5.th ed. Sigma; 2006. http://www.sigmaaldrich.com/technical-documents/articles/biology/rbi-handbook.htmlPDF icon Sigma-RBI Handbook of Receptor Classification and Signal Transduction: VEGF Receptors (263.92 KB)
Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, et al.. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (80- ) [Internet]. 1997;276(5317):1423 - 5. http://view.ncbi.nlm.nih.gov/pubmed/9162011PDF icon Michael Jeltsch et al., Science 1997 (293.65 KB)
Jeltsch M, Jha SKumar, Tvorogov D, Anisimov A, Leppänen V-M, Holopainen T, et al.. CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation. Circulation [Internet]. 2014;129(19). http://circ.ahajournals.org/content/early/2014/02/19/CIRCULATIONAHA.113.002779.abstractPDF icon Postprint of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation (6.6 MB)PDF icon Postprint of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation (Suppl.) (2.38 MB)PDF icon Published version of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated... (incl. suppl.) (23.21 MB)
Jeltsch M. VEGFR-3 Ligands and Lymphangiogenesis [Internet]. University of Helsinki. 2002. http://ethesis.helsinki.fi/julkaisut/mat/bioti/vk/jeltschPDF icon Michael Jeltsch, PhD Thesis, 2002 (1.75 MB)
Jeltsch M, Leppänen V-M, Saharinen P, Alitalo K. Receptor Tyrosine Kinase-Mediated Angiogenesis. Cold Spring Harbor Perspectives in Biology [Internet]. 2013;5(9). http://cshperspectives.cshlp.org/content/5/9/a009183PDF icon Jeltsch et al. (2013): Tyrosine Kinase-Mediated Angiogenesis. CSH Persp Biol (934.46 KB)
Jeltsch M. From molecular biology to a causal treatment of lymphatic system disorders [Internet]. 38. Jahreskongress der Deutschen Gesellschaft für Lymphologie e. V. Halle (Saale), Germany: Deutsche Gesellschaft für Lymphologie; 2014. https://jeltsch.org/abstract-Halle2014

Pages